Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSCINASDAQ:FBRXNASDAQ:PLURNASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSCICOSCIENS Biopharma$3.60+7.8%$3.15$1.96▼$6.77$11.33M0.8912,661 shs2,961 shsFBRXForte Biosciences$7.85+0.3%$6.71$4.11▼$28.68$51.68M2.82154,197 shs20,895 shsPLURPluri$5.21+3.4%$4.57$3.33▼$7.13$40.49M0.7715,598 shs4,060 shsRNTXRein Therapeutics$2.21-6.4%$1.79$1.35▼$4.40$48.96M1.7855,104 shs19,890 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSCICOSCIENS Biopharma+7.78%+1.41%+27.66%+30.43%+359,999,900.00%FBRXForte Biosciences+0.26%+23.04%+8.13%-34.58%+30,564.06%PLURPluri+3.37%-10.63%+36.39%+12.77%-14.45%RNTXRein Therapeutics-6.36%+25.57%+33.94%-9.43%+220,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AFBRXForte Biosciences2.69 of 5 stars3.53.00.00.01.71.71.3PLURPluri0.3884 of 5 stars0.03.00.00.02.50.80.0RNTXRein TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSCICOSCIENS Biopharma 0.00N/AN/AN/AFBRXForte Biosciences 3.00Buy$32.50314.01% UpsidePLURPluri 0.00N/AN/AN/ARNTXRein Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CSCI, FBRX, PLUR, and RNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $61.00(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSCICOSCIENS Biopharma$9.59M1.18N/AN/A$14.99 per share0.24FBRXForte BiosciencesN/AN/AN/AN/A$24.30 per shareN/APLURPluri$678K59.72N/AN/A($0.42) per share-12.40RNTXRein TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSCICOSCIENS Biopharma-$16.55M-$5.80N/A∞N/A-428.43%-95.93%-45.66%N/AFBRXForte Biosciences-$31.48M-$16.29N/AN/AN/AN/A-151.43%-118.92%N/APLURPluri-$20.89M-$5.53N/A∞N/A-3,551.49%-2,778.13%-83.61%N/ARNTXRein Therapeutics-$15.73M-$3.47N/AN/AN/AN/A-74.08%-27.93%N/ALatest CSCI, FBRX, PLUR, and RNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025FBRXForte Biosciences-$0.89-$1.37-$0.48-$1.37N/AN/A5/15/2025Q1 2025RNTXRein Therapeutics-$0.21-$0.25-$0.04-$0.25N/AN/A5/13/2025Q1 2025CSCICOSCIENS BiopharmaN/A-$1.16N/A-$1.16N/A$1.50 million5/13/2025Q3 2025PLURPluriN/A-$0.94N/A-$0.94N/A$0.43 million4/9/2025Q4 2024CSCICOSCIENS Biopharma-$3.48-$2.15+$1.33-$2.15$1.10 million$3.32 million4/7/2025Q4 2024RNTXRein TherapeuticsN/A-$0.26N/A-$1.89N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSCICOSCIENS BiopharmaN/A3.463.05FBRXForte BiosciencesN/A2.062.06PLURPluri4.445.045.04RNTXRein TherapeuticsN/A3.303.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSCICOSCIENS Biopharma0.73%FBRXForte Biosciences77.63%PLURPluri16.59%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipCSCICOSCIENS Biopharma0.10%FBRXForte Biosciences5.90%PLURPluri10.20%RNTXRein Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSCICOSCIENS Biopharma203.15 million3.77 millionN/AFBRXForte Biosciences56.58 million6.20 millionOptionablePLURPluri1507.77 million6.28 millionOptionableRNTXRein Therapeutics922.15 million20.56 millionN/ACSCI, FBRX, PLUR, and RNTX HeadlinesRecent News About These CompaniesRein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16 at 7:54 PM | finanznachrichten.deRein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15 at 4:09 PM | prnewswire.comRein Therapeutics begins trial for idiopathic pulmonary fibrosis treatmentMay 13, 2025 | msn.comRein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 12, 2025 | finanznachrichten.deRein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 12, 2025 | prnewswire.comRein Therapeutics to integrate Qureight’s platform in trial of IPF treatmentMay 2, 2025 | msn.comRein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPFMay 1, 2025 | prnewswire.comRein Therapeutics to Present at The Citizens Life Sciences Conference 2025April 30, 2025 | prnewswire.comRein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International ConferenceApril 28, 2025 | prnewswire.comRein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory DiseasesApril 23, 2025 | prnewswire.comRein Therapeutics reports IPF and PASC-F treatment progressApril 18, 2025 | uk.investing.comRein Therapeutics’ LTI-2355 peptide shows therapuetic potential in studyApril 16, 2025 | markets.businessinsider.comRein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-FApril 15, 2025 | prnewswire.comRein Therapeutics, Inc.: Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 8, 2025 | finanznachrichten.deRein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 7, 2025 | prnewswire.comRein Therapeutics Inc. (RNTX)March 25, 2025 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSCI, FBRX, PLUR, and RNTX Company DescriptionsCOSCIENS Biopharma NASDAQ:CSCI$3.60 +0.26 (+7.78%) Closing price 05/16/2025 03:49 PM EasternExtended Trading$3.55 -0.05 (-1.39%) As of 05/16/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Forte Biosciences NASDAQ:FBRX$7.85 +0.02 (+0.26%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$7.92 +0.07 (+0.89%) As of 05/16/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Pluri NASDAQ:PLUR$5.21 +0.17 (+3.37%) Closing price 05/16/2025 03:59 PM EasternExtended Trading$5.05 -0.16 (-3.07%) As of 05/16/2025 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Rein Therapeutics NASDAQ:RNTX$2.21 -0.15 (-6.36%) As of 05/16/2025 04:00 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
